Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 5, 2021
Event: Entry into a Material Definitive Agreement for a private placement offering.
Key Financial Metrics
This filing reports on a capital raise rather than operational financial performance. Specific metrics include:
- Gross Proceeds: Approximately $4.5 million from the sale of Units.
- Net Proceeds: Estimated at approximately $4.0 million.
- Use of Proceeds: General corporate purposes, including working capital.
- Placement Agent Fee: 8% of gross proceeds plus expense reimbursement up to $40,000.
- Warrant Exercise Price: $4.85 per share.
Note: The filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement with eleven institutional accredited investors. The transaction involves the issuance of Units consisting of:
- Common shares.
- 0.66 of a warrant per Unit to purchase common shares.
The closing of the sale is expected on or about February 12, 2021, subject to customary conditions.
Outlook, Risks, and Unusual Items
Management Commentary: The company intends to use the net proceeds to fund general corporate purposes and working capital.
Terms and Conditions:
- Warrant Terms: Warrants are exercisable six months after the closing date and expire five and a half years from the closing date. They include cashless exercise provisions upon certain events.
- Ownership Limitations: Holders cannot exercise warrants if doing so would result in beneficial ownership exceeding 4.99% (or 9.99% at the holder's election) of outstanding common shares.
- Registration Rights: The Company agreed to file registration statements covering the resale of the Shares and Warrant Shares.
- Placement Agent: Roth Capital Partners, LLC was engaged as the exclusive placement agent on a best-efforts basis.
Investor Verification Checklist
- Confirm the actual closing date and final net proceeds received (expected ~Feb 12, 2021).
- Verify the total number of common shares and warrants issued upon closing.
- Review the impact of the new share issuance on existing shareholder dilution.
- Monitor the filing of the registration statement for the resale of shares and warrant shares.
- Check subsequent filings for updates on the utilization of the $4.0 million in net proceeds.